Gilead’s selonsertib fails to meet primary endpoint in Phase 3 NASH study

Image: NASH is a chronic and progressive liver disease characterized by fat accumulation and inflammation in the liver. Photo: courtesy of interphasesolution / FreeDigitalPhotos.net.